MedTrace Logo

A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease

NCT07566429 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-05-05

No results posted yet for this study

Summary

The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).

Conditions

  • Parkinson Disease

Interventions

DRUG

AB-1005

Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Sponsors & Collaborators

  • AskBio Inc

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-27
Primary Completion
2028-12-15
Completion
2032-06-15
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07566429 on ClinicalTrials.gov